VistaGen is known best for its proprietary stem cell technology used in their novel bioassay systems to provide superior toxicity testing of new drug candidates. The company’s Human Clinical Trials in a Test TubeTM platform is designed to provide accurate and early prediction of potential heart and liver toxicity issues for new drugs, allowing pharmaceutical companies to avoid spending billions of dollars bringing a potentially unsafe drug to market. In particular, VistaGen’s CardioSafe 3D bioassay system is focused on assessing in vivo cardiac effects of new drug candidates.

The company is also developing AV-101, a unique prodrug candidate for the treatment of neuropathic pain, a serious and chronic condition affecting approximately 1.8 million people in the U.S. alone. The drug’s strength is its remarkable ability to rapidly and efficiently transport across the blood-brain barrier, where it can convert into an effective blocker at the site of seizures and neural damage in the brain and spinal cord. AV-101 is currently in Phase 1b development in the U.S. VistaGen believes that the safety studies completed in its Phase 1 clinical program may also enable Phase 2 development of AV-101 for depression, epilepsy, and Parkinson’s disease.

For additional information, visit the company’s website at www.VistaGen.com

Let us hear your thoughts below: